Allergan was founded in 1987 and is a leader in the biopharma, biotechnology, and pharmaceutical industries. In 2019, it became a part of AbbVie, a company dedicated to discovering and delivering innovative medicines to address current and future health challenges. AbbVie focuses on key therapeutic areas such as immunology, oncology, neuroscience, eye care, virology, women’s health, and gastroenterology, in addition to products and services within its Allergan Aesthetics portfolio.
The most recent notable investment in Allergan was a $23.60M post-IPO equity investment on 19 September 2012. As of now, there is no information available about the specific investors involved. Allergan's headquarters are located in Ireland.
For more information about AbbVie and its developments, please visit the website at www.abbvie.com and follow @AbbVie on LinkedIn for updates.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $23.60M | - | 19 Sep 2012 | |
| Post-IPO Equity | $5.90M | - | 12 Nov 2009 | |
| Post-IPO Equity | Unknown | 1 |
|
01 Jan 2009 |
No recent news or press coverage available for Allergan.
We care about your data, and we'd love to use cookies make your experience better.
